1
|
Tang D, Kang R. SQSTM1 is a therapeutic target for infection and sterile inflammation. Cytokine 2023; 169:156317. [PMID: 37542833 DOI: 10.1016/j.cyto.2023.156317] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Accepted: 07/31/2023] [Indexed: 08/07/2023]
Abstract
Inflammation represents a fundamental immune response triggered by various detrimental stimuli, such as infections, tissue damage, toxins, and foreign substances. Protein degradation plays a crucial role in regulating the inflammatory process at multiple levels. The identification of sequestosome 1 (SQSTM1, also known as p62) protein as a binding partner of lymphocyte-specific protein tyrosine kinase in 1995 marked a significant milestone. Subsequent investigations unveiled the activity of SQSTM1 to interact with diverse unstructured substrates, including proteins, organelles, and pathogens, facilitating their delivery to the lysosome for autophagic degradation. In addition to its well-established intracellular functions, emerging studies have reported the active secretion or passive release of SQSTM1 by immune or non-immune cells, orchestrating the inflammatory responses. These distinct characteristics render SQSTM1 a critical therapeutic target in numerous human diseases, including infectious diseases, rheumatoid arthritis, inflammatory bowel disease, pancreatitis, asthma, chronic obstructive pulmonary disease, and cardiovascular diseases. This review provides a comprehensive overview of the structure and modulation of SQSTM1, discusses its intracellular and extracellular roles in inflammation, and highlights its significance in inflammation-related diseases. Future investigations focusing on elucidating the precise localization, structure, post-translational modifications of SQSTM1, as well as the identification of additional interacting partners, hold promise for unravelling further insights into the multifaceted functions of SQSTM1.
Collapse
Affiliation(s)
- Daolin Tang
- Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
| | - Rui Kang
- Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
| |
Collapse
|
2
|
Chaitanya NSN, Tammineni P, Nagaraju GP, Reddy ABM. Pleiotropic roles of evolutionarily conserved signaling intermediate in toll pathway (ECSIT) in pathophysiology. J Cell Physiol 2022; 237:3496-3504. [DOI: 10.1002/jcp.30832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 06/23/2022] [Accepted: 07/04/2022] [Indexed: 11/10/2022]
Affiliation(s)
- Nyshadham S. N. Chaitanya
- Department of Animal Biology, School of Life Sciences University of Hyderabad Hyderabad Telangana India
| | - Prasad Tammineni
- Department of Animal Biology, School of Life Sciences University of Hyderabad Hyderabad Telangana India
| | | | - Aramati BM Reddy
- Department of Animal Biology, School of Life Sciences University of Hyderabad Hyderabad Telangana India
| |
Collapse
|
3
|
sGRP78 enhances selective autophagy of monomeric TLR4 to regulate myeloid cell death. Cell Death Dis 2022; 13:587. [PMID: 35798718 PMCID: PMC9262968 DOI: 10.1038/s41419-022-05048-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 06/21/2022] [Accepted: 06/27/2022] [Indexed: 01/21/2023]
Abstract
Soluble glucose regulated protein 78 (sGRP78) has long been suggested as a mediator resolution of inflammation. We previously reported that sGRP78 induced the rapid endocytosis of TLR4 with defective TLR4 signaling. To elucidate the underlying mechanisms, in this study, we investigated how sGRP78 influenced the behavior and trafficking of TLR4 in myeloid cells. It was found that sGRP78 promoted LPS endocytosis with monomeric TLR4. This internalized monomeric TLR4 formed complexes with p62-LC3, and was degraded in autolysosomes. Furthermore, the sGRP78-enhanced autophagy-dependent TLR4 degradation caused apoptosis and ferroptosis in myeloid cells, contributing to the sGRP78-mediated resolution of inflammation. These reports establish innovative mechanisms for endotoxin clearance and immune regulation by TLR4 degradation, linking innate immunity with multiple ancient processes, including autophagy, apoptosis, and ferroptosis, together through a shared resolution-associated molecular pattern (RAMP)-sGRP78.
Collapse
|
4
|
Kim MJ, Min Y, Jeong SK, Son J, Kim JY, Lee JS, Kim DH, Lee JS, Chun E, Lee KY. USP15 negatively regulates lung cancer progression through the TRAF6-BECN1 signaling axis for autophagy induction. Cell Death Dis 2022; 13:348. [PMID: 35422093 PMCID: PMC9010460 DOI: 10.1038/s41419-022-04808-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 03/17/2022] [Accepted: 03/30/2022] [Indexed: 12/22/2022]
Abstract
TNF receptor-associated factor 6 (TRAF6)-BECN1 signaling axis plays a pivotal role in autophagy induction through ubiquitination of BECN1, thereby inducing lung cancer migration and invasion in response to toll-like receptor 4 (TLR4) stimulation. Herein, we provide novel molecular and cellular mechanisms involved in the negative effect of ubiquitin-specific peptidase 15 (USP15) on lung cancer progression. Clinical data of the TCGA and primary non-small cell lung cancer (NSCLC) patients (n = 41) revealed that the expression of USP15 was significantly downregulated in lung cancer patients. Importantly, USP15-knockout (USP15KO) A549 and USP15KO H1299 lung cancer cells generated with CRISPR-Cas9 gene-editing technology showed increases in cancer migration and invasion with enhanced autophagy induction in response to TLR4 stimulation. In addition, biochemical studies revealed that USP15 interacted with BECN1, but not with TRAF6, and induced deubiquitination of BECN1, thereby attenuating autophagy induction. Notably, in primary NSCLC patients (n = 4) with low expression of USP15, 10 genes (CCNE1, MMP9, SFN, UBE2C, CCR2, FAM83A, ETV4, MYO7A, MMP11, and GSDMB) known to promote lung cancer progression were significantly upregulated, whereas 10 tumor suppressor genes (FMO2, ZBTB16, FCN3, TCF21, SFTPA1B, HPGD, SOSTDC1, TMEM100, GDF10, and WIF1) were downregulated, providing clinical relevance of the functional role of USP15 in lung cancer progression. Taken together, our data demonstrate that USP15 can negatively regulate the TRAF6-BECN1 signaling axis for autophagy induction. Thus, USP15 is implicated in lung cancer progression.
Collapse
Affiliation(s)
- Mi-Jeong Kim
- Department of Immunology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
| | - Yoon Min
- Department of Immunology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
| | - Soo-Kyung Jeong
- R&D Center, CHA Vaccine Institute, Seongnam-si, 13493, Republic of Korea
| | - Juhee Son
- Department of Immunology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
| | - Ji Young Kim
- Department of Immunology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
| | - Ji Su Lee
- Department of Immunology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
| | - Duk-Hwan Kim
- Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
- Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
| | - Joo Sang Lee
- Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea
| | - Eunyoung Chun
- R&D Center, CHA Vaccine Institute, Seongnam-si, 13493, Republic of Korea.
| | - Ki-Young Lee
- Department of Immunology, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
- Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Samsung Medical Center, Sungkyunkwan University, Seoul, 06351, Republic of Korea.
- Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon, 16419, Republic of Korea.
| |
Collapse
|
5
|
Son J, Kim MJ, Lee JS, Kim JY, Chun E, Lee KY. Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation. Immune Netw 2021; 21:e37. [PMID: 34796041 PMCID: PMC8568915 DOI: 10.4110/in.2021.21.e37] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 09/28/2021] [Accepted: 10/20/2021] [Indexed: 12/14/2022] Open
Abstract
Hepatitis B virus X (HBx) protein has been reported as a key protein regulating the pathogenesis of HBV-induced hepatocellular carcinoma (HCC). Recent evidence has shown that HBx is implicated in the activation of autophagy in hepatic cells. Nevertheless, the precise molecular and cellular mechanism by which HBx induces autophagy is still controversial. Herein, we investigated the molecular and cellular mechanism by which HBx is involved in the TRAF6-BECN1-Bcl-2 signaling for the regulation of autophagy in response to TLR4 stimulation, therefore influencing the HCC progression. HBx interacts with BECN1 (Beclin 1) and inhibits the association of the BECN1-Bcl-2 complex, which is known to prevent the assembly of the pre-autophagosomal structure. Furthermore, HBx enhances the interaction between VPS34 and TRAF6-BECN1 complex, increases the ubiquitination of BECN1, and subsequently enhances autophagy induction in response to LPS stimulation. To verify the functional role of HBx in liver cancer progression, we utilized different HCC cell lines, HepG2, SK-Hep-1, and SNU-761. HBx-expressing HepG2 cells exhibited enhanced cell migration, invasion, and cell mobility in response to LPS stimulation compared to those of control HepG2 cells. These results were consistently observed in HBx-expressed SK-Hep-1 and HBx-expressed SNU-761 cells. Taken together, our findings suggest that HBx positively regulates the induction of autophagy through the inhibition of the BECN1-Bcl-2 complex and enhancement of the TRAF6-BECN1-VPS34 complex, leading to enhance liver cancer migration and invasion.
Collapse
Affiliation(s)
- Juhee Son
- Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Korea
| | - Mi-Jeong Kim
- Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Korea
| | - Ji Su Lee
- Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Korea
| | - Ji Young Kim
- Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Korea
| | | | - Ki-Young Lee
- Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Korea.,Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea.,Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon, Korea
| |
Collapse
|
6
|
Meng H, Fan L, Zhang CJ, Zhu L, Liu P, Chen J, Bao X, Pu Z, Zhu MS, Xu Y. Synthetic VSMCs induce BBB disruption mediated by MYPT1 in ischemic stroke. iScience 2021; 24:103047. [PMID: 34553133 PMCID: PMC8441154 DOI: 10.1016/j.isci.2021.103047] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 06/14/2021] [Accepted: 08/24/2021] [Indexed: 12/20/2022] Open
Abstract
Vascular smooth muscle cells (VSMCs) have been widely recognized as key players in regulating blood-brain barrier (BBB) function, and their roles are unclear in ischemic stroke. Myosin phosphatase target subunit 1 (MYPT1) is essential for VSMC contraction and maintaining healthy vasculature. We generated VSMC-specific MYPT1 knockout (MYPT1SMKO) mice and cultured VSMCs infected with Lv-shMYPT1 to explore phenotypic switching of VSMCs and the accompanied impacts on BBB integrity. We found that MYPT1 deficiency induced phenotypic switching of synthetic VSMCs, which aggravated BBB disruption. Proteomic analysis identified evolutionarily conserved signaling intermediates in Toll pathways (ECSIT) as a downstream molecule that promotes activation of synthetic VSMCs and contributed to IL-6 expression. Knocking down ECSIT rescued phenotypic switching of VSMCs and BBB disruption. Additionally, inhibition of IL-6 decreased BBB permeability. These findings reveal that MYPT1 deficiency activated phenotypic switching of synthetic VSMCs and induced BBB disruption through ECSIT-IL-6 signaling after ischemic stroke. MYPT1 deficiency induces activation of synthetic VSMCs and aggravates BBB disruption Synthetic VSMCs release more IL-6 to destroy BBB in a contact-independent way MYPT1-ECSIT-IL-6 signaling pathway regulates synthetic VSMC-mediated BBB disruption
Collapse
Affiliation(s)
- Hailan Meng
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Lizhen Fan
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Cun-Jin Zhang
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Liwen Zhu
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Pinyi Liu
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Jian Chen
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Xinyu Bao
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Zhijun Pu
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| | - Min-Sheng Zhu
- Model Animal Research Center, Nanjing University, Nanjing 210061, China.,Ministry of Education (MOE) Key Laboratory of Model Animal for Disease Study, Nanjing University, Nanjing 210061, China
| | - Yun Xu
- Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210008, China.,Institute of Brain Sciences, Nanjing University, Nanjing 210008, China.,Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing 210008, China.,Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing 210008, China.,Nanjing Neuropsychiatry Clinic Medical Center, Nanjing 210008, China
| |
Collapse
|
7
|
Tang J, Li Y, Xia S, Li J, Yang Q, Ding K, Zhang H. Sequestosome 1/p62: A multitasker in the regulation of malignant tumor aggression (Review). Int J Oncol 2021; 59:77. [PMID: 34414460 PMCID: PMC8425587 DOI: 10.3892/ijo.2021.5257] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Accepted: 07/12/2021] [Indexed: 02/06/2023] Open
Abstract
Sequestosome 1 (SQSTM1)/p62 is an adapter protein mainly involved in the transportation, degradation and destruction of various proteins that cooperates with components of autophagy and the ubiquitin-proteasome degradation pathway. Numerous studies have shown that SQSTM1/p62 functions at multiple levels, including involvement in genetic stability or modification, post-transcriptional regulation and protein function. As a result, SQSTM1/p62 is a versatile protein that is a critical core regulator of tumor cell genetic stability, autophagy, apoptosis and other forms of cell death, malignant growth, proliferation, migration, invasion, metastasis and chemoradiotherapeutic response, and an indicator of patient prognosis. SQSTM1/p62 regulates these processes via its distinct molecular structure, through which it participates in a variety of activating or inactivating tumor-related and tumor microenvironment-related signaling pathways, particularly positive feedback loops and epithelial-mesenchymal transition-related pathways. Therefore, functioning as a proto-oncogene or tumor suppressor gene in various types of cancer and tumor-associated microenvironments, SQSTM1/p62 is capable of promoting or retarding malignant tumor aggression, giving rise to immeasurable effects on tumor occurrence and development, and on patient treatment and prognosis.
Collapse
Affiliation(s)
- Jinlong Tang
- Department of Pathology and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
| | - Yuan Li
- Department of Pediatrics, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang 310000, P.R. China
| | - Shuli Xia
- Department of Pathology, Zhejiang University School of Medicine, Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy, Chinese Academy of Medical Sciences, Hangzhou, Zhejiang 310058, P.R. China.,Key Laboratory of Disease Proteomics of Zhejiang Province, Hangzhou, Zhejiang 310058, P.R. China
| | - Jinfan Li
- Department of Pathology and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
| | - Qi Yang
- Department of Pathology and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
| | - Kefeng Ding
- Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China,Cancer Center of Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
| | - Honghe Zhang
- Department of Pathology, Zhejiang University School of Medicine, Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy, Chinese Academy of Medical Sciences, Hangzhou, Zhejiang 310058, P.R. China.,Key Laboratory of Disease Proteomics of Zhejiang Province, Hangzhou, Zhejiang 310058, P.R. China
| |
Collapse
|
8
|
Zhang W, Feng C, Jiang H. Novel target for treating Alzheimer's Diseases: Crosstalk between the Nrf2 pathway and autophagy. Ageing Res Rev 2021; 65:101207. [PMID: 33144123 DOI: 10.1016/j.arr.2020.101207] [Citation(s) in RCA: 92] [Impact Index Per Article: 30.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 10/02/2020] [Accepted: 10/27/2020] [Indexed: 02/06/2023]
Abstract
In mammals, the Keap1-Nrf2-ARE pathway (henceforth, "the Nrf2 pathway") and autophagy are major intracellular defence systems that combat oxidative damage and maintain homeostasis. p62/SQSTM1, a ubiquitin-binding autophagy receptor protein, links the Nrf2 pathway and autophagy. Phosphorylation of p62 dramatically enhances its affinity for Keap1, which induces Keap1 to release Nrf2, and the p62-Keap1 heterodimer recruits LC3 and mediates the permanent degradation of Keap1 in the selective autophagy pathway. Eventually, Nrf2 accumulates in the cytoplasm and then translocates into the nucleus to activate the transcription of downstream genes that encode antioxidant enzymes, which protect cells from oxidative damage. Since Nrf2 also upregulates the expression of the p62 gene, a p62-Keap1-Nrf2 positive feedback loop is created that further enhances the protective effect on cells. Studies have shown that the p62-activated noncanonical Nrf2 pathway is an important marker of neurodegenerative diseases. The p62-Keap1-Nrf2 positive feedback loop and the Nrf2 pathway are involved in eliminating the ROS and protein aggregates induced by AD. Therefore, maintaining the homeostasis of the p62-Keap1-Nrf2 positive feedback loop, which is a bridge between the Nrf2 pathway and autophagy, may be a potential target for the treatment of AD.
Collapse
Affiliation(s)
- Weiwei Zhang
- Department of Health Laboratory Technology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, Liaoning 110122, People's Republic of China
| | - Cong Feng
- Department of Health Laboratory Technology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, Liaoning 110122, People's Republic of China
| | - Hong Jiang
- Department of Health Laboratory Technology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, Liaoning 110122, People's Republic of China.
| |
Collapse
|
9
|
Yi YS. Caspase-11 Noncanonical Inflammasome: A Novel Key Player in Murine Models of Neuroinflammation and Multiple Sclerosis. Neuroimmunomodulation 2021; 28:195-203. [PMID: 34044393 DOI: 10.1159/000516064] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 03/18/2021] [Indexed: 11/19/2022] Open
Abstract
Inflammasomes are intracellular protein complexes consisting of the pattern recognition receptors and inflammatory molecules in the inflamed cells. In response to various ligands, inflammasomes play a pivotal role to execute the inflammatory responses by inducing the pyroptosis and the secretion of pro-inflammatory cytokines, interleukin (IL)-1β, and IL-18. Unlike canonical inflammasomes, including NOD-like receptor family inflammasomes, such as NLRP1, NLRP3, NLRC4, and absence in melanoma 2 inflammasomes, noncanonical inflammasomes, such as mouse caspase-11 and human caspase-4/5 were recently discovered, and their roles in the inflammatory responses have been poorly understood. However, emerging studies have been successfully demonstrating the regulatory roles of these noncanonical inflammasomes on inflammatory responses and the pathogenesis of inflammatory/autoimmune diseases. This review summarizes and discusses the recent studies investigating the regulatory roles of the caspase-11 noncanonical inflammasome in neuroinflammation and the pathogenesis of multiple sclerosis (MS), which provides the insight for the validation of caspase-11 noncanonical inflammasome to develop novel and promising therapeutics for MS.
Collapse
Affiliation(s)
- Young-Su Yi
- Department of Life Sciences, Kyonggi University, Suwon, Republic of Korea
| |
Collapse
|
10
|
AMPKα1 Regulates Lung and Breast Cancer Progression by Regulating TLR4-Mediated TRAF6-BECN1 Signaling Axis. Cancers (Basel) 2020; 12:cancers12113289. [PMID: 33172060 PMCID: PMC7694660 DOI: 10.3390/cancers12113289] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 11/02/2020] [Accepted: 11/03/2020] [Indexed: 12/21/2022] Open
Abstract
Simple Summary TRAF6-BECN1 signaling axis in TLR4 signal plays an essential role for the autophagy induction, thereby it regulates cancer migration and invasion. Here we show that AMPKα1, one of the isoforms of AMPK, is functionally involved in autophagy induction by regulating the TRAF6-BECN1 signaling axis. In this context, AMPKα1-knockout lung or breast cancer cells exhibited the attenuation of cancer cell migration and invasion induced by TLR4 simulation. Additionally, we could find that the expression of AMPKα1 is positively associated with gene expressions related to autophagy, migration, and metastasis of cancer cells in primary non-small cell lung cancers (NSCLCs). These findings demonstrate that AMPKα1 plays a pivotal role in cancer progression by regulating the TRAF6-BECN1 signaling axis for autophagy induction. Abstract TRAF6-BECN1 signaling axis is critical for autophagy induction and functionally implicated in cancer progression. Here, we report that AMP-activated protein kinase alpha 1 (AMPKα1, PRKAA1) is positively involved in autophagy induction and cancer progression by regulating TRAF6-BECN1 signaling axis. Mechanistically, AMPKα1 interacted with TRAF6 and BECN1. It also enhanced ubiquitination of BECN1 and autophagy induction. AMPKα1-knockout (AMPKα1KO) HEK293T or AMPKα1-knockdown (AMPKα1KD) THP-1 cells showed impaired autophagy induced by serum starvation or TLR4 (Toll-like receptor 4) stimulation. Additionally, AMPKα1KD THP-1 cells showed decreases of autophagy-related and autophagosome-related genes induced by TLR4. AMPKα1KO A549 cells exhibited attenuation of cancer migration and invasion induced by TLR4. Moreover, primary non-small cell lung cancers (NSCLCs, n = 6) with low AMPKαl levels showed markedly decreased expression of genes related to autophagy, cell migration and adhesion/metastasis, inflammation, and TLRs whereas these genes were significantly upregulated in NSCLCs (n = 5) with high AMPKαl levels. Consistently, attenuation of cancer migration and invasion could be observed in AMPKα1KO MDA-MB-231 and AMPKα1KO MCF-7 human breast cancer cells. These results suggest that AMPKα1 plays a pivotal role in cancer progression by regulating the TRAF6-BECN1 signaling axis for autophagy induction.
Collapse
|
11
|
p62 is Negatively Implicated in the TRAF6-BECN1 Signaling Axis for Autophagy Activation and Cancer Progression by Toll-Like Receptor 4 (TLR4). Cells 2020; 9:cells9051142. [PMID: 32384667 PMCID: PMC7290749 DOI: 10.3390/cells9051142] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 04/23/2020] [Accepted: 05/02/2020] [Indexed: 02/07/2023] Open
Abstract
Toll-like receptors (TLRs) induce the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and autophagy through the TNF (Tumor necrosis factor) receptor-associated factor 6 (TRAF6)-evolutionarily conserved signaling intermediate in Toll pathways (ECSIT) and TRAF6-BECN1 signaling axes, respectively. Having shown that p62 negatively regulates Toll-like receptor 4 (TLR4)-mediated signaling via TRAF6-ECSIT signaling axis, we herein investigated whether p62 is functionally implicated in the TRAF6-BECN1 signaling axis, thereby regulating cancer cell migration and invasion. p62 interacted with TRAF6 and BECN1, to interrupt the functional associations required for TRAF6-BECN1 complex formation, leading to inhibitions of BECN1 ubiquitination and autophagy activation. Importantly, p62-deficient cancer cells, such as p62-knockdown (p62KD) SK-HEP-1, p62KD MDA-MB-231, and p62-knockout (p62KO) A549 cells, showed increased activation of autophagy induced by TLR4 stimulation, suggesting that p62 negatively regulates autophagy activation. Moreover, these p62-deficient cancer cells exhibited marked increases in cell migration and invasion in response to TLR4 stimulation. Collectively, these results suggest that p62 is negatively implicated in the TRAF6-BECN1 signaling axis, thereby inhibiting cancer cell migration and invasion regulated by autophagy activation in response to TLR4 stimulation.
Collapse
|
12
|
Hu Z, Pan Y, Cheng A, Zhang X, Wang M, Chen S, Zhu D, Liu M, Yang Q, Wu Y, Zhao X, Huang J, Zhang S, Mao S, Ou X, Yu Y, Zhang L, Liu Y, Tian B, Pan L, Rehman MU, Yin Z, Jia R. Autophagy Promotes Duck Tembusu Virus Replication by Suppressing p62/SQSTM1-Mediated Innate Immune Responses In Vitro. Vaccines (Basel) 2020; 8:vaccines8010022. [PMID: 31941042 PMCID: PMC7157248 DOI: 10.3390/vaccines8010022] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 01/08/2020] [Accepted: 01/10/2020] [Indexed: 12/16/2022] Open
Abstract
Duck Tembusu virus (DTMUV) has recently appeared in ducks in China and the key cellular determiners for DTMUV replication in host cells remain unknown. Autophagy is an evolutionarily conserved cellular process that has been reported to facilitate flavivirus replication. In this study, we utilized primary duck embryo fibroblast (DEF) as the cell model and found that DTMUV infection triggered LC3-II increase and polyubiquitin-binding protein sequestosome 1 (p62) decrease, confirming that complete autophagy occurred in DEF cells. The induction of autophagy by pharmacological treatment increased DTMUV replication in DEF cells, whereas the inhibition of autophagy with pharmacological treatments or RNA interference decreased DTMUV replication. Inhibiting autophagy enhanced the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and interferon regulatory factor 7 (IRF7) pathways and increased the p62 protein level in DTMUV-infected cells. We further found that the overexpression of p62 decreased DTMUV replication and inhibited the activation of the NF-κB and IRF7 pathways, and changes in the NF-κB and IRF7 pathways were consistent with the level of phosphorylated TANK-binding kinase 1 (p-TBK1). Opposite results were found in p62 knockdown cells. In summary, we found that autophagy-mediated p62 degradation acted as a new strategy for DTMUV to evade host innate immunity.
Collapse
Affiliation(s)
- Zhiqiang Hu
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Yuhong Pan
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Anchun Cheng
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Xingcui Zhang
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Mingshu Wang
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Shun Chen
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Dekang Zhu
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Mafeng Liu
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Qiao Yang
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Ying Wu
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Xinxin Zhao
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Juan Huang
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Shaqiu Zhang
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Sai Mao
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Xumin Ou
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Yanling Yu
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Ling Zhang
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Yunya Liu
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Bin Tian
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Leichang Pan
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Mujeeb Ur Rehman
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Zhongqiong Yin
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
| | - Renyong Jia
- Research Center of Avian Disease, Sichuan Agricultural University, Chengdu 611130, China; (Z.H.); (Y.P.); (A.C.); (X.Z.); (M.W.); (S.C.); (D.Z.); (M.L.); (Q.Y.); (Y.W.); (X.Z.); (J.H.); (S.Z.); (S.M.); (X.O.); (Y.Y.); (L.Z.); (Y.L.); (B.T.); (L.P.); (M.U.R.)
- Institute of Preventive Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
- Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China;
- Correspondence:
| |
Collapse
|